Bicycle Therapeutics Pivots from Bladder Cancer Challenger, Zelenectide, Amidst Intense Competition
admin Bicycle Therapeutics, a clinical-stage biopharmaceutical company leveraging its proprietary "Bicycle" technology to develop a novel...
drug development
R1 Therapeutics Launches with $77.5 Million, Unveiling Novel Oral Treatment for Chronic Kidney Disease Complication
Redwood City, California – March 17, 2026 – In a significant move set to potentially...
Structure Therapeutics’ Aleniglipron Shows “Injectable-Like Efficacy” in Promising Phase 2 Obesity Trial, Intensifying Oral GLP-1 Race
Structure Therapeutics, a rapidly emerging biotech firm, has announced compelling Phase 2 trial results for...
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer
CytomX Therapeutics, a biopharmaceutical company focused on developing novel cancer therapies, announced on March 16,...
FDA Revolutionizes Product Safety Monitoring with Unified Surveillance Dashboard, Consolidating Disparate Systems for Enhanced Utility and Efficiency
The U.S. Food and Drug Administration (FDA) has announced a significant overhaul of its product...
Eli Lilly Urges FDA to Recall Compounded Zepbound, Citing "Dangerous" Impurities and "Unknown Risks" in Unauthorized Formulations
Eli Lilly has intensified its campaign against compounded versions of its blockbuster obesity drug Zepbound...
FDA Streamlines Biosimilar Approval Pathway to Boost Competition and Lower Drug Costs
The U.S. Food and Drug Administration (FDA) has announced significant draft guidance aimed at accelerating...
Biopharma Sector Navigates Layoffs, Regulatory Hurdles, and Clinical Breakthroughs as Companies Adapt to Evolving Market Dynamics
The biopharmaceutical landscape is currently characterized by a complex interplay of strategic restructurings, significant workforce...
GSK’s Arexvy Secures Expanded FDA Approval for Younger Adults with High-Risk Conditions, Marking a Pivotal Win in a Challenging Regulatory Landscape
The U.S. Food and Drug Administration (FDA) has granted an expanded approval for GSK’s respiratory...
FDA Clears First-of-Its-Kind Allogeneic Stem Cell Therapy for Epilepsy Human Trials, Signifying a Global Biotech Shift
The U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for...
